ZA201400236B - Combination als therapy - Google Patents
Combination als therapyInfo
- Publication number
- ZA201400236B ZA201400236B ZA2014/00236A ZA201400236A ZA201400236B ZA 201400236 B ZA201400236 B ZA 201400236B ZA 2014/00236 A ZA2014/00236 A ZA 2014/00236A ZA 201400236 A ZA201400236 A ZA 201400236A ZA 201400236 B ZA201400236 B ZA 201400236B
- Authority
- ZA
- South Africa
- Prior art keywords
- combination
- als therapy
- als
- therapy
- combination als
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507381P | 2011-07-13 | 2011-07-13 | |
| US201161544533P | 2011-10-07 | 2011-10-07 | |
| US201261637759P | 2012-04-24 | 2012-04-24 | |
| US201261637770P | 2012-04-24 | 2012-04-24 | |
| US201261646699P | 2012-05-14 | 2012-05-14 | |
| PCT/US2012/046523 WO2013010015A2 (en) | 2011-07-13 | 2012-07-12 | Combination als therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201400236B true ZA201400236B (en) | 2014-10-29 |
Family
ID=47506929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/00236A ZA201400236B (en) | 2011-07-13 | 2014-01-10 | Combination als therapy |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10272082B2 (enExample) |
| EP (1) | EP2731611B1 (enExample) |
| JP (2) | JP6145946B2 (enExample) |
| KR (1) | KR101951220B1 (enExample) |
| CN (2) | CN109316480A (enExample) |
| AU (2) | AU2012281042B2 (enExample) |
| BR (1) | BR112014000742A2 (enExample) |
| CA (1) | CA2849213A1 (enExample) |
| EA (2) | EA028060B1 (enExample) |
| HK (1) | HK1197178A1 (enExample) |
| IL (1) | IL230391B (enExample) |
| IN (1) | IN2014DN00200A (enExample) |
| PH (1) | PH12014500094A1 (enExample) |
| SG (1) | SG10201605707UA (enExample) |
| WO (1) | WO2013010015A2 (enExample) |
| ZA (1) | ZA201400236B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
| US20170042890A1 (en) * | 2014-04-29 | 2017-02-16 | Cytokinetics, Inc. | Methods of reducing decline in vital capacity |
| ES2751300T3 (es) * | 2014-11-21 | 2020-03-31 | Biohaven Therapeutics Ltd | Formulación sublingual de riluzol |
| EA201791110A1 (ru) * | 2014-11-21 | 2017-11-30 | Биохэвен Фармасьютикэл Холдинг Компани Лтд. | Сублингвальное введение рилузола |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| CA3018635C (en) | 2016-03-25 | 2023-09-26 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| WO2021055890A1 (en) | 2019-09-20 | 2021-03-25 | Icahn School Of Medicine At Mount Sinai | Controlled release formulations of riluzole and their uses |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| IT1156732B (it) | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
| US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
| US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
| US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
| US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
| JPH0641135A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP2002517396A (ja) | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症性化合物 |
| ES2213611T3 (es) | 1999-10-08 | 2004-09-01 | Grunenthal Gmbh | Derivados biciclicos de imidazo-3-il-amina. |
| JP2003511456A (ja) | 1999-10-08 | 2003-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二環状イミダゾ−５−イル−アミン誘導体 |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| US20030083318A1 (en) * | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
| US20040235801A1 (en) * | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| WO2005013894A2 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
| JP2007521296A (ja) | 2003-07-01 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | 高眼圧の治療のための眼科用組成物 |
| EP1694323A4 (en) | 2003-12-19 | 2009-05-13 | Elixir Pharmaceuticals Inc | METHOD FOR TREATING A DISEASE |
| CA2553670A1 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc. | Anti-viral therapeutics |
| WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1796467A4 (en) | 2004-09-24 | 2009-07-01 | Janssen Pharmaceutica Nv | INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| WO2006088836A2 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US8796293B2 (en) | 2006-04-25 | 2014-08-05 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
| WO2008016648A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| DK2583970T3 (en) | 2006-08-02 | 2015-11-16 | Cytokinetics Inc | Certain chemical entities, compositions, and methods comprising imidazopyrimidines |
| SI2583970T1 (sl) * | 2006-08-02 | 2016-03-31 | Cytokinetics, Inc. | Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| CN105693730A (zh) | 2006-10-19 | 2016-06-22 | 西格诺药品有限公司 | 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途 |
| WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
| MX2009007661A (es) | 2007-01-19 | 2009-12-14 | Ardea Biosciences Inc | Inhibidores de mek. |
| WO2008121333A1 (en) | 2007-03-30 | 2008-10-09 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| EP2018854A1 (en) * | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| US7989469B2 (en) | 2008-02-04 | 2011-08-02 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| EP2323691A2 (en) * | 2008-07-11 | 2011-05-25 | Glaxo Group Limited | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
| JP5930278B2 (ja) | 2008-11-25 | 2016-06-08 | ユニバーシティー オブ ロチェスター | Ｍｌｋ阻害剤および使用方法 |
| EP2228054A1 (en) * | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| RU2012101792A (ru) | 2009-06-19 | 2013-07-27 | Нопп Ньюросайенсиз, Инк. | Композиции и способы для лечения бокового амиотрофического склероза |
| US20150065525A1 (en) | 2012-04-02 | 2015-03-05 | Cytokinetics, Inc. | Methods for improving diaphragm function |
| SG11201406359TA (en) | 2012-04-11 | 2014-11-27 | Cytokinetics Inc | Improving resistance to skeletal muscle fatigue |
| US20170042890A1 (en) | 2014-04-29 | 2017-02-16 | Cytokinetics, Inc. | Methods of reducing decline in vital capacity |
-
2012
- 2012-07-12 WO PCT/US2012/046523 patent/WO2013010015A2/en not_active Ceased
- 2012-07-12 EA EA201490011A patent/EA028060B1/ru not_active IP Right Cessation
- 2012-07-12 AU AU2012281042A patent/AU2012281042B2/en not_active Ceased
- 2012-07-12 KR KR1020147000783A patent/KR101951220B1/ko not_active Expired - Fee Related
- 2012-07-12 CA CA2849213A patent/CA2849213A1/en not_active Abandoned
- 2012-07-12 JP JP2014520335A patent/JP6145946B2/ja not_active Expired - Fee Related
- 2012-07-12 PH PH1/2014/500094A patent/PH12014500094A1/en unknown
- 2012-07-12 EA EA201791043A patent/EA201791043A1/ru unknown
- 2012-07-12 CN CN201811116043.0A patent/CN109316480A/zh active Pending
- 2012-07-12 IN IN200DEN2014 patent/IN2014DN00200A/en unknown
- 2012-07-12 US US14/131,649 patent/US10272082B2/en not_active Expired - Fee Related
- 2012-07-12 CN CN201280034661.5A patent/CN104039148A/zh active Pending
- 2012-07-12 SG SG10201605707UA patent/SG10201605707UA/en unknown
- 2012-07-12 BR BR112014000742A patent/BR112014000742A2/pt not_active Application Discontinuation
- 2012-07-12 HK HK14110537.3A patent/HK1197178A1/xx unknown
- 2012-07-12 EP EP12811325.5A patent/EP2731611B1/en active Active
-
2014
- 2014-01-09 IL IL230391A patent/IL230391B/en active IP Right Grant
- 2014-01-10 ZA ZA2014/00236A patent/ZA201400236B/en unknown
-
2016
- 2016-10-13 AU AU2016244263A patent/AU2016244263A1/en not_active Abandoned
-
2017
- 2017-04-28 JP JP2017090313A patent/JP2017128610A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014500094A1 (en) | 2014-03-17 |
| US20140243344A1 (en) | 2014-08-28 |
| AU2016244263A1 (en) | 2016-11-03 |
| AU2012281042A1 (en) | 2014-01-30 |
| EA201791043A1 (ru) | 2017-09-29 |
| WO2013010015A3 (en) | 2014-05-15 |
| KR20140074270A (ko) | 2014-06-17 |
| KR101951220B1 (ko) | 2019-02-22 |
| CA2849213A1 (en) | 2013-01-17 |
| EA201490011A1 (ru) | 2014-08-29 |
| HK1197178A1 (en) | 2015-01-09 |
| US10272082B2 (en) | 2019-04-30 |
| AU2012281042B2 (en) | 2016-07-14 |
| WO2013010015A2 (en) | 2013-01-17 |
| IN2014DN00200A (enExample) | 2015-06-05 |
| CN109316480A (zh) | 2019-02-12 |
| JP2014520856A (ja) | 2014-08-25 |
| NZ619924A (en) | 2016-02-26 |
| SG10201605707UA (en) | 2016-09-29 |
| JP2017128610A (ja) | 2017-07-27 |
| EP2731611B1 (en) | 2019-09-18 |
| EP2731611A2 (en) | 2014-05-21 |
| IL230391B (en) | 2019-03-31 |
| CN104039148A (zh) | 2014-09-10 |
| JP6145946B2 (ja) | 2017-06-14 |
| BR112014000742A2 (pt) | 2016-08-23 |
| EP2731611A4 (en) | 2015-02-18 |
| EA028060B1 (ru) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201305897B (en) | Combination therapy | |
| GB201212513D0 (en) | Therapeutic agents | |
| IL222481A0 (en) | Combination therapy | |
| EP2552323A4 (en) | COMBINATION THERAPY | |
| ZA201400120B (en) | Combination therapy | |
| GB201106803D0 (en) | Sonodynamic therapy | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| PL2489413T3 (pl) | Przyrząd terapeutyczny | |
| GB201217439D0 (en) | Combination therapy | |
| ZA201400236B (en) | Combination als therapy | |
| GB201217704D0 (en) | Therapeutic agents | |
| PL2723344T3 (pl) | Złożony środek leczniczy zawierający monoterpen | |
| ZA201502595B (en) | Therapeutic methods | |
| EP2701744A4 (en) | COMBINATION THERAPY | |
| GB201207305D0 (en) | Therapy | |
| EP2879707A4 (en) | COMBINATION THERAPY | |
| GB201005394D0 (en) | Therapy | |
| EP2704731A4 (en) | TREATMENT OF AVIAN ORIGIN | |
| GB201106630D0 (en) | Cancer therapy | |
| EP2629766A4 (en) | COMBINATION THERAPY | |
| GB201102913D0 (en) | Novel therapeutic | |
| GB201114226D0 (en) | Combination therapy | |
| GB201120096D0 (en) | Novel therapy | |
| GB201101128D0 (en) | Therapeutic agents |